Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITVIN: Imiquimod vs Surgery for Vulvar Intraepithelial Neoplasia
NCT01861535Phase 3Completed
- Sponsor
- Medical University of Graz
- Start
- Jun 2013
- Primary completion
- Feb 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in vulvar intraepithelial neoplasia (VIN) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Complete clinical response at 6 months. Started Jun 2013; status: completed.
02
Drugs
imiquimod
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NCT01861535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861535.